Taken together, the reports stand as an indictment of the entire programmatic ecosystem. Critics say the unsuitable ...

While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account ...

Seoul: Celltrion, a leading South Korean biopharmaceutical company, on Thursday said its business will remain largely ...

SEOUL, May 15 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday its business will ...

Shamekh IV plans to invest $5.8 billion in the global production of intravenous fluids and genomic products, starting in Saudi Arabia under the subsidiary Shamekh Life Sciences. B ...

Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European markets.

Blake Powers: I’m excited about Blue Fin’s panel on biosimilars. Cell and gene therapy is also a ... moving beyond email and Zoom to build stronger, face-to-face relationships with industry partners.

In 2023, SEEQC announced a partnership with Nvidia to build an “all-digital, ultra-low-latency chip-to-chip link between quantum computers and GPUs.” In January 2025, SEEQC raised a $30 ...

Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its reference product, Lantus. Increases were seen across retail, mail order ...

According to the industry on the 30th, the U.S. District Court for New Jersey dismissed J&J’s motion for a preliminary injunction regarding Samsung Bioepis’s sale of the Stelara biosimilar ...

Both the Generics and Biosimilars segments underperformed, though the latter was notably weaker, missing consensus by 9%. International sales were 22% below expectations, partly reflecting the ...